DCM
PTGX icon

Dupont Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Dupont Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,127
Closed -$143K – 1109
2022
Q4 		$143K Buy
+13,127
New +$111K 0.01% 863
2022
Q3 		– Sell
-16,499
Closed -$131K – 1655
2022
Q2 		$131K Buy
+16,499
New +$199K 0.01% 1125

Other funds holding PTGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dupont Capital Management's PTGX Position: Q1 2023 in Review

Dupont Capital Management sold out of Protagonist Therapeutics (PTGX) in Q1 2023, closing a stake of 13,127 shares — an estimated $143K sold.

Dupont Capital Management first reported a position in PTGX in Q2 2022 and held it in 2 quarters. The position peaked at $143K in Q4 2022. 137 funds tracked by Wall St. Rank hold PTGX as of Q1 2023.

  • Dupont Capital Management reported no remaining Protagonist Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Dupont Capital Management sold 13,127 Protagonist Therapeutics shares in Q1 2023, an estimated $143K.
  • Dupont Capital Management first reported a position in Protagonist Therapeutics in Q2 2022 and held it in 2 quarters.
  • Dupont Capital Management's Protagonist Therapeutics position peaked at $143K in Q4 2022.
  • 137 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2023.

Based on Dupont Capital Management's 13F filing for Q1 2023, filed 28 Apr 2023.